133 results about "Cystatin C" patented technology

Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein.

The invention provides a cysteine protease inhibitor C test kit, wherein the kit comprises a reagent R1 and a reagent R2, the reagent R2 is a reaction solution for promoting specific binding of an antigen and an antibody, the reagent R2 is a polystyrene latex particle mixture coated by an anti-human cystatin C antibody and is put in a proper buffer solution. The polystyrene latex particle mixture in the reagent R2 is a mixture of large-diameter polystyrene latex particles and small-diameter polystyrene latex particles. The kit is high in detection sensitivity, high in accuracy, good in linearity within the test range, good in stability and low in production cost.

There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved.

The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and / or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and / or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and / or activity.

Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases.

The invention relates to a method for predicting the risk of the end-stage renal disease in a patient diagnosed with diabetic nephropathy through renal puncture biopsy within three years. The method comprises the following steps that clinical data of a large number of patients who are diagnosed with the diabetic nephropathy through the renal puncture biopsy pathology and do not suffer from the end-stage renal disease is collected, whether or not the patients suffer from the end-stage renal disease is judged after 3 years of follow-up visit; according to the follow-up visit results, diabetic nephropathy pathological grades, cystatin C and 3GFR data of the patients diagnosed with the diabetic nephropathy through the renal puncture biopsy are collected, and a predictive risk equation of a prediction model is obtained. Accordingly, the risk of the patients suffering from the end-stage renal disease is helped to be judged according to initial detection data, early intervention is achieved,and the progress of the renal disease is delayed. According to the risk prediction method, early clinical risk prediction and reasonable systematic management can be provided for more patients definitely diagnosed with the diabetic nephropathy.

There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved.